MACE, Arrhythmia, Pericardial Effusion and Survival
Conditions
Brief summary
The goal of this observational study is to learn about cardiac safety monitoring after thoracic radiotherapy in adults with thoracic tumors. The main question it aims to answer is: Dose dynamic monitoring of cardiac biomarkers, electrocardiography, echocardiography, peripheral blood immune cell subsets, cytokines, chemokines, lipid profiles, and lipid metabolism markers help identify early clinical or subclinical cardiac changes after thoracic radiotherapy? Are cardiac substructure radiation dose parameters associated with early cardiac safety outcomes? Participants receiving thoracic radiotherapy as part of their regular medical care will complete cardiac safety assessments at the end of radiotherapy, 1 month after radiotherapy, and 3 months after radiotherapy.
Interventions
None listed
Sponsors
Hebei Medical University Fourth Hospital
National Natural Science Foundation of China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients willing to participate the research and sign the informed consent file; Patients aged ≥18 years; KPS≥70; Pathological diagnosis for lung cancer, metastatic lung cancer, esophageal cacner, breast cancer and thymus tumor; Patients received thoracic radiotherapy; No functional heart disease; LVEF≥50%
Exclusion criteria
Patients received thoracic radiotherapy previously; Patients with severe organic and functional disease; Unqualified patients with sufficient reasons; Cannot or no willing to sign the informed consent file
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cardiac safety | From enrollment to the end of thoracic radiotherapy at 3 months |
Countries
China
Contacts
CONTACTYajing Wu, MD
PRINCIPAL_INVESTIGATORWu
Hebei Medical University Fourth Hospital
Outcome results
None listed